 PRINCETON, N.J.--BUSINESS WIRE--UroGen Pharma Ltd. Nasdaq: URGN, a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Company has entered into a strategic funding agreement with RTW Investments, LP and its affiliated entities RTW. Under the terms of the agreement, subject to customary closing conditions, UroGen will receive 75 million in upfront cash from RTW in return for tier 